CBIIF News and Press, Skylight Health Group From 09/19/19

Medicinal cannabis data group CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) has announced it is expanding its market presence in the UK, boosting CBII stock by 5%. The company, which specializes in research and data collection to offer a suite of technology solutions in the medicinal c...

Company strengthens market presence in United Kingdom with licensing of Electronic Data Capture Technology in partnership with UK-based MyAccess Clinics MyAccess Clinics to use CB2’s software within multi-clinic operation in the UK for data input and management Software will allow...

Company recruits prominent Colombian naturopathic and integrative medicine physician Dr. Paola Cubillos, MD, ND to lead medical cannabis research programs to advance emerging market Rapid growth in market presence from Licensed Producers and cannabis-focused product manufacturers create p...

TORONTO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“ CB2 ” or the “ Company ”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), ...

TORONTO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII; OTCQB:CBIIF), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community and healthcare sector, ...

As legal cannabis transforms North America, a number of major industries are beginning to develop their own strategies for new potential products and services. In the medical cannabis space, major pharmaceutical companies are collecting a growing body of evidence that suggests cannabis has ...

TORONTO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has appointed corpora...

TORONTO, July 31, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has appointed former ...

NEWS HIGHLIGHTS CB2 Insights has been selected as exclusive research technology platform for the UK’s largest medical cannabis Pilot - Project TWENTY21 Project TWENTY21 aims to enroll 20,000 patients into the Pilot and CB2 Insights was selected as the platform on which to buil...

TORONTO, July 09, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has successfully comp...